Robert T. Schooley

Robert T. Schooley

Auto-generated profile, based on publicly available information

Robert T. Schooley

Department of Medicine, University of California San Diego

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RSRobert T. Schooley
Robert T. Schooley
BBBiswajit Biswas
Biswajit Biswas
JGJason Gill
Jason Gill
AHAdriana Hernandez-Morales
Adriana Hernandez-Morales
JLJacob Lancaster
Jacob Lancaster
THTheron Hamilton
Theron Hamilton
Widespread antibiotic use in clinical medicine and the livestock industry has contributed to the global spread of multidrug-resistant (MDR) bacterial pathogens, includingAcinetobacter baumannii. We report on a method used to produce a personalized bacteriophage-based therapeutic treatment for a 68-year-old diabetic patient with necrotizing pancreatitis complicated by an MDRA. baumanniiinfection. Despite multiple antibiotic courses and efforts at percutaneous drainage of a pancreatic pseudocyst, the patient deteriorated over a 4-month period. In the absence of effective antibiotics, two laboratories identified nine different bacteriophages with lytic activity for anA. baumanniiisolate from the patient. Administration of these bacteriophages intravenously and percutaneously into the abscess cavities was associated with reversal of the patient's downward clinical trajectory, clearance of theA. baumanniiinfection, and a return to health. The outcome of this case suggests that the methods described here for the production of bacteriophage therapeutics could be applied to similar cases and that more concerted efforts to investigate the use of therapeutic bacteriophages for MDR bacterial infections are warranted.

27 January 2022 in Annual Review of Medicine
Verified
Journal Article
Closed access
GHGraham Hatfull
Graham Hatfull
RDRebekah M. Dedrick
Rebekah M. Dedrick
RSRobert T. Schooley
Robert T. Schooley
Antibiotic resistance in bacterial pathogens presents a substantial threat to the control of infectious diseases. Development of new classes of antibiotics has slowed in recent years due to pressures of cost and market profitability, and there is a strong need for new antimicrobial therapies. The therapeutic use of bacteriophages has long been considered, with numerous anecdotal reports of success. Interest in phage therapy has been renewed by recent clinical successes in case studies with personalized phage cocktails, and several clinical trials are in progress. We discuss recent progress in the therapeutic use of phages and contemplate the key factors influencing the opportunities and challenges. With strong safety profiles, the main challenges of phage therapeutics involve strain variation among clinical isolates of many pathogens, battling phage resistance, and the potential limitations of host immune responses. However, the opportunities are considerable, with the potential to enhance current antibiotic efficacy, protect newly developed antibiotics, and provide a last resort in response to complete antibiotic failure.

7 July 2022 in Nature
Verified
Journal Article
Open access
PDF file
SKSmruthi Karthikeyan
Smruthi Karthikeyan
JLJoshua I. Levy
Joshua I. Levy
PHPeter De Hoff
Peter De Hoff
GHGreg Humphrey
Greg Humphrey
ABAmanda Birmingham
Amanda Birmingham
RKRob Knight
Rob Knight
As SARS-CoV-2 continues to spread and evolve, detecting emerging variants early is critical for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited resources, participation, or testing and/or sequencing capacity, which can also introduce biases1–3. SARS-CoV-2 RNA concentration in wastewater successfully tracks regional infection dynamics and provides less biased abundance estimates than clinical testing4,5. Tracking virus genomic sequences in wastewater would improve community prevalence estimates and detect emerging variants. However, two factors limit wastewater-based genomic surveillance: low-quality sequence data and inability to estimate relative lineage abundance in mixed samples. Here we resolve these critical issues to perform a high-resolution, 295-day wastewater and clinical sequencing effort, in the controlled environment of a large university campus and the broader context of the surrounding county. We developed and deployed improved virus concentration protocols and deconvolution software that fully resolve multiple virus strains from wastewater. We detected emerging variants of concern up to 14 days earlier in wastewater samples, and identified multiple instances of virus spread not captured by clinical genomic surveillance. Our study provides a scalable solution for wastewater genomic surveillance that allows early detection of SARS-CoV-2 variants and identification of cryptic transmission.

22 November 2013 in Virology Journal
Verified
Journal Article
Open access
PDF file
MCMiriam Cohen
Miriam Cohen
XZXing-Quan Zhang
Xing-Quan Zhang
HSHooman P Senaati
Hooman P Senaati
HCHui-Wen Chen
Hui-Wen Chen
NVNissi M Varki
Nissi M Varki
PGPascal Gagneux
Pascal Gagneux
Influenza A virus (IAV) neuraminidase (NA) cleaves sialic acids (Sias) from glycans. Inhibiting NA with oseltamivir suppresses both viral infection, and viral release from cultured human airway epithelial cells. The role of NA in viral exit is well established: it releases budding virions by cleaving Sias from glycoconjugates on infected cells and progeny virions. The role of NA in viral entry remains unclear. Host respiratory epithelia secrete a mucus layer rich in heavily sialylated glycoproteins; these could inhibit viral entry by mimicking sialylated receptors on the cell surface. It has been suggested that NA allows influenza to penetrate the mucus by cleaving these sialylated decoys, but the exact mechanism is not yet established.

21 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
CSClaudia Ramirez Sanchez
Claudia Ramirez Sanchez
FGFrancis Gonzales
Francis Gonzales
MBMaureen Buckley
Maureen Buckley
BBBiswajit Biswas
Biswajit Biswas
MHMatthew Henry
Matthew Henry
SASaima Aslam
Saima Aslam
Successful joint replacement is a life-enhancing procedure with significant growth in the past decade. Prosthetic joint infection occurs rarely; it is a biofilm-based infection that is poorly responsive to antibiotic alone. Recent interest in bacteriophage therapy has made it possible to treat some biofilm-based infections, as well as those caused by multidrug-resistant pathogens, successfully when conventional antibiotic therapy has failed. Here, we describe the case of a 61-year-old woman who was successfully treated after a second cycle of bacteriophage therapy administered at the time of a two-stage exchange procedure for a persistent methicillin-sensitive Staphylococcus aureus (MSSA) prosthetic knee-joint infection. We highlight the safety and efficacy of both intravenous and intra-articular infusions of bacteriophage therapy, a successful outcome with a single lytic phage, and the development of serum neutralization with prolonged treatment.

17 September 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
RSRobert T. Schooley
Robert T. Schooley
ACAaron F. Carlin
Aaron F. Carlin
JBJames R. Beadle
James R. Beadle
NVNadejda Valiaeva
Nadejda Valiaeva
XZXing-Quan Zhang
Xing-Quan Zhang
KHKarl Hostetler
Karl Hostetler
Remdesivir (RDV; GS-5734) is currently the only FDA-approved antiviral drug for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The drug is approved for use in adults or children 12 years or older who are hospitalized for the treatment of COVID-19 on the basis of an acceleration of clinical recovery for inpatients with this disease.